Viking Therapeutics, Inc. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
Viking Therapeutics, Inc. (VKTX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$39.87 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-07-29
- Viking Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$47.71M, a 523.60% decline year-over-year.
- Viking Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $11.26M, a 91.96% decline year-over-year.
- Viking Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was $140.11M.
- Viking Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$18.26M.
- Viking Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $139.14M.
- Viking Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$28.69M, a 251.70% decline from fiscal 2023.
- Viking Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $18.91M, a 79.81% increase from fiscal 2022.
- Viking Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $10.52M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$39.87M 10-Q · filed 2026-07-29 | |||
| 2026-03-31 | -$47.71M 10-Q · filed 2026-04-30 | |||
| 2025-12-31 | $139.14M 10-K · filed 2026-02-11 | |||
| 2025-09-30 | $73.72M 10-Q · filed 2025-10-23 | |||
| 2025-06-30 | $7.21M 10-Q · filed 2026-07-29 | |||
| 2025-03-31 | $11.26M 10-Q · filed 2026-04-30 | |||
| 2024-12-31 | -$28.69M 10-K · filed 2026-02-11 | |||
| 2024-09-30 | -$5.09M 10-Q · filed 2025-10-23 | |||
| 2024-06-30 | -$11.56M 10-Q · filed 2025-07-23 | |||
| 2024-03-31 | $140.11M 10-Q · filed 2025-04-24 | |||
| 2023-12-31 | $18.91M 10-K · filed 2026-02-11 | |||
| 2023-09-30 | $633.00K 10-Q · filed 2024-10-23 | |||
| 2023-06-30 | $32.90M 10-Q · filed 2024-07-24 | |||
| 2023-03-31 | -$18.26M 10-Q · filed 2024-04-25 | |||
| 2022-12-31 | $10.52M 10-K · filed 2025-02-26 | |||
| 2022-09-30 | $3.44M 10-Q · filed 2023-10-25 | |||
| 2022-06-30 | -$9.97M 10-Q · filed 2022-07-27 | |||
| 2021-12-31 | -$2.75M 10-K · filed 2024-02-07 | |||
| 2021-06-30 | -$20.29M 10-Q · filed 2022-07-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |